Browse drugs

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

… observed, suggesting an immune-mediated antitumor mechanism of CJRB-101. A total of 42 patients were enrolled in the low-dose cohort (o…

…nificant difference in mean bodyweight was found between groups.Nivolumab was administered to 108 patients: 64 (weight 62.29 ± 32.06kg) r…

… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…

… may negatively impact both PFS and OS in patients treated with pembrolizumab. These findings, consistent with previous literature, highlight…

…nd dose reductions in 20%.Conclusion and Relevance Weight-based pembrolizumab dosing achieved pCR and safety results consistent with those fr…

…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…

…ation-induced cells death.Conclusions ICT01 in combination with pembrolizumab generated clinically meaningful anti-tumor efficacy in 2L CPI-r…

…gainst human SW1990 pancreatic tumor cell line when compared to pembrolizumab. HCW11-040 was also found to neutralize the immunosuppresivenes…

…cyte count (ALC) identifies a subgroup unlikely to benefit from pembrolizumab.Methods We performed a single-center retrospective study of adu…

…ypermutated profile (+190 genes), showing a durable response to pembrolizumab.Methods A 57-year-old male was diagnosed with moderately differ…

…n while modulating immunosuppressive regulatory T cell (T reg). HM16390 is a novel, long-acting IL-2 analog engineered with precise bin…